Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 2/20 | 0.40 |
| ▸ | F3 | P13726 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110913 | 0.86 | SCN10A (0.54) | SMN1; SMN2ALDH1A1HPGDHRH4SCN10A | |
| SCHEMBL10248233 | 0.86 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A | |
| SCHEMBL1358509 | 0.84 | HRH4 (0.41) | SMN1; SMN2ALDH1A1HPGDHRH4F7 | |
| SCHEMBL9866407 | 0.82 | NPSR1 (0.58) | SMN1; SMN2ALDH1A1L3MBTL1HPGDHRH4 | |
| SCHEMBL23619188 | 0.81 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A | |
| SCHEMBL846855 | 0.80 | SCN10A (0.58) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A | |
| SCHEMBL10005347 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A | |
| SCHEMBL18862125 | 0.79 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1HPGDHRH4F7 | |
| SCHEMBL14491782 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A | |
| SCHEMBL2732982 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1L3MBTL1HPGDSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140242046-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | Childern's Medical Center Corporation (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242046-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | Childern's Medical Center Corporation (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-7217720-B2 | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | SMN1; SMN2 1240/4885ALDH1A1 2404/4885L3MBTL1 151/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 1715/4885ALDH1A1 1890/4885L3MBTL1 1306/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | SMN1; SMN2 1240/4885ALDH1A1 2404/4885L3MBTL1 151/4885 |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | DOT1L, ASH1L, CARM1 | SMN1; SMN2 3312/4885ALDH1A1 1001/4885L3MBTL1 474/4885 |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | SMN1; SMN2 4018/4885ALDH1A1 2215/4885L3MBTL1 4627/4885 |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | SMN1; SMN2 1819/4885ALDH1A1 1884/4885L3MBTL1 412/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885ALDH1A1 592/4885L3MBTL1 699/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 1715/4885ALDH1A1 1890/4885L3MBTL1 1306/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885ALDH1A1 592/4885L3MBTL1 699/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 1466/4885ALDH1A1 2705/4885L3MBTL1 1042/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885ALDH1A1 592/4885L3MBTL1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.